Aug 05, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line
TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales.
Aug 05, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Company News for Aug 5, 2025
Companies in The News Are: ...
Aug 04, 2025 • Benzinga
NEUTRAL
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results - CommScope Holding Co ( NASDAQ:COMM ) , BT Brands ( NASDAQ:BTBD )
U.S. stocks traded higher midway through trading, with the S&P 500 gaining more than 1% on Monday. The Dow traded up 1.27% to 44,141.11 while the NASDAQ climbed 1.82% to 21,026.44. The S&P 500 also rose, gaining, 1.37% to 6,323.33. Communication services shares jumped by 2.3% on Monday.
Aug 04, 2025 • Benzinga
SOMEWHAT-BULLISH
Why Is TG Therapeutics Stock Falling Monday? - TG Therapeutics ( NASDAQ:TGTX )
Q2 EPS rose to 17 cents from 4 cents but missed the 19 cents consensus; revenue reached $141.2 million vs. $146.4 million expected. Briumvi Q2 U.S. revenue hit $138.8 million, up 91% YoY, beating guidance of $135 million. The next correction is closer than you think.
Aug 04, 2025 • Motley Fool
SOMEWHAT-BULLISH
TG Therapeutics Q2 Revenue Up 91%
TG Therapeutics ( NASDAQ:TGTX ) , which specializes in treatments for autoimmune diseases, released its second-quarter 2025 earnings on August 4, 2025. The headline news was strong sales growth for BRIUMVI, its infusion therapy for relapsing multiple sclerosis, prompting management to raise its ...
Aug 04, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
TG Therapeutics ( TGTX ) Misses Q2 Earnings Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -46.88% and +3.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?